- ►prsjournal.com JF Arevalo, M Maia, HW Flynn, M Saravia, RL … - British Journal of …, 2008 - bjo.bmj.com Results: Eleven eyes (patients) out of 211 intravitreal injections (5.2%) that developed or had
progression of TRD were identified. All eyes had PDR refractory to panretinal photocoagulation
(PRP). Nine patients had type 1 diabetes mellitus (DM), and two patients had type 2 DM. ... Cited by 36 - Related articles - BL Direct - All 5 versions
- ►prsjournal.com [PDF] E Chen, CH PARK - Retina, 2006 - journals.lww.com Retinal neovascularization rarely occurs in association with choroidal hemangioma.1 Shields
et al2 studied the clinical manifestations of 200 consecutive cases of circumscribed choroidal
hemangioma and observed a choroidal neovascular membrane in 3 cases and neo- ... Cited by 67 - Related articles - BL Direct - All 4 versions
S Rizzo, F Genovesi-Ebert, E Di Bartolo, A Vento, S … - Graefe's Archive for …, 2008 - Springer Abstract Purpose To evaluate the use of preoperative intravitreal bevacizumab (IVB) in patients
undergoing pars plana vitrectomy (PPV) for complications of proliferative diabetic retinopathy
(PDR). Methods We studied 22 patients with severe PDR. A preoperative complexity ... Cited by 16 - Related articles - BL Direct - All 2 versions
K Ishikawa, S Honda, Y Tsukahara, A Negi - Eye, 2007 - nature.com All cases showed minimum bleeding during surgical dissection of fibrovascular membrane. Two
cases receiving bevacizumab 7 days before the surgery showed strong fibrosis and adhesion
of fibrovascular membrane, resulted in some surgical complications. The cases having ... Cited by 20 - Related articles - All 3 versions
S Moradian, H Ahmadieh, M Malihi, M Soheilian, … - Graefe's Archive for …, 2008 - Springer Abstract Background Vitreous concentration of vascular endothelial growth factor (VEGF) rises
significantly during prolifera- tive diabetic retinopathy (PDR). Bevacizumab (Avastin) is a humanized
monoclonal antibody to VEGF. Intravitreal administration of bevacizumab (IVB) has ... Cited by 11 - Related articles - All 2 versions
M Shimura, T Nakazawa, K Yasuda, T Shiono, T … - American journal of …, 2008 - Elsevier Before the injection, foveal thickness and VA were 522.3 ± 91.3 μm and 0.64 ± 0.28 μm in the
triamcinolone-injected eye, and 527.6 ± 78.8 μm and 0.61 ± 0.18 μm in the bevacizumab-injected
eye, respectively; there was no significant difference between the eyes. One week after ... Cited by 37 - Related articles - All 34 versions
JF Arevalo, L Wu, JG Sanchez, M Maia, MJ Saravia, CF … - Eye, 2007 - nature.com Forty-four eyes of 33 patients with PDR and a mean age of 57.2-years (range: 23–82 years) participated
in the study. Thirty-three eyes (75%) had previous panretinal photocoagulation (PRP).
Twenty-seven eyes (61.4%) showed total regression of RN on fundus examination with ... Cited by 17 - Related articles - All 3 versions
[CITATION] JF Arevalo, L Wu 2, JG Sanchez, M Maia 3
A Minnella, C Savastano, L Ziccardi, A … - Acta …, 2008 - interscience.wiley.com Methods: This interventional case series study included 15 eyes of 10 patients with bilateral
PDR: 13 eyes with severe PDR and active new vessels (NV) and two eyes with recurrent vitreous
haemorrhages. Study eyes received a single intravitreal injection of 1.25 mg (0.05 ml) ... Cited by 15 - Related articles - All 3 versions
CM Yang, PT Yeh, CH Yang, MS Chen - American Journal of Ophthalmology, 2008 - Elsevier Sixteen eyes (15 patients) that underwent primary pars plana vitrectomy for active proliferative
diabetic retinopathy (PDR) were prospectively enrolled with a follow-up period of six months
or more. These cases received an intravitreal injection of bevacizumab (1.25 mg/0.05 ml) ... Cited by 8 - Related articles - All 23 versions
